July 6, 2017

Caribou Biosciences Appoints Steven B. Kanner, Ph.D. as Chief Scientific Officer

BERKELEY, Calif.–Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.

“We are delighted to welcome such a well-respected and talented scientist as Steve to our team,” said Rachel Haurwitz, Ph.D., President and Chief Executive Officer of Caribou. “Caribou is continuing to make exciting progress in our gene editing technology development and Steve’s wealth of experience will help further accelerate our efforts.”

During his career, Dr. Kanner has held a number of research leadership roles at prominent life sciences organizations, including Bristol-Myers Squibb, Astex Pharmaceuticals, and Agensys/Astellas Pharma. Most recently, Dr. Kanner served as Vice President of Discovery Biology at Arrowhead Pharmaceuticals, where he helped lead the discovery and development of novel RNAi-based therapeutics for oncology and genetic disease programs. During his time at Bristol-Myers Squibb, he facilitated a discovery program ultimately leading to the development and launch of Sprycel® (dasatinib), a treatment for chronic myeloid leukemia.

Read More

Back to News